Survival outcomes following complete mediastinal lymphadenectomy or selective mediastinal lymphadenectomy in patients with stage I-IIIA non-small cell lung cancer: protocol for a systematic review and meta-analysis.

Jianfeng Xu, Jinxing Lai, Xiongfeng Huang, Yuxi Ren, Qiao Chen, Weijuan Li
Author Information
  1. Jianfeng Xu: Fuzhou Medical College of Nanchang University, Fuzhou, China.
  2. Jinxing Lai: Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, China.
  3. Xiongfeng Huang: Fuzhou Medical College of Nanchang University, Fuzhou, China xiongfeng186@126.com. ORCID
  4. Yuxi Ren: Jiangxi University of Chinese Medicine, Nanchang, China.
  5. Qiao Chen: Jiangxi University of Chinese Medicine, Nanchang, China.
  6. Weijuan Li: Fuzhou Medical College of Nanchang University, Fuzhou, China.

Abstract

INTRODUCTION: Lung cancer remains the largest cause of cancer-related deaths worldwide. Surgical removal of non-small cell lung cancer (NSCLC) has the potential to achieve a cure, although there is ongoing debate regarding the significance of removing mediastinal nodes and the optimal extent of lymph node excision. The purpose of this research is to assess the survival outcomes in patients diagnosed with stage I-IIIA NSCLC who received either complete mediastinal lymphadenectomy (CML) or selective mediastinal lymphadenectomy (SML).
METHODS AND ANALYSIS: The protocol follows the guidelines recommended in Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols, and this meta-analysis will be conducted in accordance with the standard methodology recommended by the Cochrane Collaboration and reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidance. We will conduct a comprehensive search for randomised controlled trials and non-randomised studies examining the effectiveness of CML compared with SML in patients with stage I-IIIA NSCLC. Two authors will perform a comprehensive search of the MEDLINE/PubMed, Embase, the Cochrane Library, CNKI, WanFang, Sinomed, VIP and Web of Science databases. There will be no restrictions on language or publication date, and the search will be conducted on 10 April 2024, with ongoing searches for new research. Reference lists will also be checked and pertinent journals will be hand searched. The primary outcomes include overall survival (OS) and disease-free survival (DFS), while the secondary outcomes consist of 1-year, 3-year and 5-year OS rates and 1-year, 3-year and 5-year DFS rates. Two independent reviewers will screen, extract data, assess quality and evaluate the potential for bias in the selected research, with a third acting as arbitrator. Subgroup analyses and sensitivity analyses are planned. The quality of the evidence will be evaluated using Grading of Recommendations Assessment, Development and Evaluation. Review Manager V.5.4 will be used for the analysis and synthesis process.
ETHICS AND DISSEMINATION: Ethical review and approval are not necessary for this study because it is based on a secondary analysis of the literature. The results will be submitted for reporting in a peer-reviewed publication.
STUDY REGISTRATION: Open Science Framework (https://doi.org/10.17605/OSF.IO/PN7UQ).

Keywords

References

  1. J Clin Epidemiol. 2011 Apr;64(4):395-400 [PMID: 21194891]
  2. Contemp Clin Trials. 2015 Nov;45(Pt A):139-45 [PMID: 26343745]
  3. J Cancer Res Ther. 2013 Sep;9 Suppl 2:S101-5 [PMID: 24135239]
  4. J Thorac Cardiovasc Surg. 2011 Mar;141(3):662-70 [PMID: 21335122]
  5. J Thorac Dis. 2017 Mar;9(3):666-674 [PMID: 28449474]
  6. J Clin Epidemiol. 2011 Apr;64(4):380-2 [PMID: 21185693]
  7. J Thorac Cardiovasc Surg. 1997 Oct;114(4):535-43 [PMID: 9338638]
  8. J Thorac Dis. 2017 Nov;9(11):4169-4170 [PMID: 29268461]
  9. N Engl J Med. 2008 Sep 25;359(13):1367-80 [PMID: 18815398]
  10. Eur J Cardiothorac Surg. 2017 Jun 1;51(6):1149-1156 [PMID: 28158453]
  11. BMJ. 2008 May 3;336(7651):995-8 [PMID: 18456631]
  12. J Natl Cancer Inst. 1959 Apr;22(4):719-48 [PMID: 13655060]
  13. J Thorac Oncol. 2008 Aug;3(8):880-6 [PMID: 18670306]
  14. Clin Lung Cancer. 2013 Mar;14(2):181-7 [PMID: 23195117]
  15. Front Oncol. 2019 Jul 24;9:642 [PMID: 31396479]
  16. Stat Med. 2002 Jun 15;21(11):1539-58 [PMID: 12111919]
  17. Cochrane Database Syst Rev. 2022 Nov 24;11:ED000160 [PMID: 36421032]
  18. PLoS One. 2014 Oct 08;9(10):e109979 [PMID: 25296033]
  19. Contemp Clin Trials. 2007 Feb;28(2):105-14 [PMID: 16807131]
  20. Thorax. 2006 Jul;61(7):597-603 [PMID: 16449262]
  21. BMJ. 2008 Apr 26;336(7650):924-6 [PMID: 18436948]
  22. J Thorac Cardiovasc Surg. 2016 May;151(5):1235-8 [PMID: 26997100]
  23. Syst Rev. 2021 Mar 29;10(1):89 [PMID: 33781348]
  24. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 [PMID: 21296855]
  25. J Thorac Cardiovasc Surg. 2018 Jul;156(1):394-402 [PMID: 29709364]
  26. J Clin Oncol. 2003 Mar 15;21(6):1029-34 [PMID: 12637467]
  27. Lung Cancer. 2002 Apr;36(1):1-6 [PMID: 11891025]
  28. Clin Chest Med. 2020 Mar;41(1):1-24 [PMID: 32008623]
  29. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004699 [PMID: 15674959]
  30. Front Oncol. 2023 Oct 04;13:1261263 [PMID: 37860201]
  31. Ann Surg. 2017 May;265(5):1025-1033 [PMID: 27232256]
  32. Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142 [PMID: 31643080]
  33. Eur J Cardiothorac Surg. 2013 Jul;44(1):e59-64 [PMID: 23644712]
  34. Syst Rev. 2015 Jan 01;4:1 [PMID: 25554246]
  35. J Public Health (Oxf). 2022 Dec 1;44(4):e588-e592 [PMID: 35352103]
  36. Oncologist. 2009 Sep;14(9):909-20 [PMID: 19726457]
  37. Ann Thorac Cardiovasc Surg. 2021 Jun 20;27(3):143-150 [PMID: 33281131]
  38. Ann Thorac Surg. 2000 Aug;70(2):358-65; discussion 365-6 [PMID: 10969645]
  39. Ann Thorac Surg. 2006 Mar;81(3):1013-9; discussion 1019-20 [PMID: 16488712]
  40. PLoS One. 2013 Sep 04;8(9):e73220 [PMID: 24023836]
  41. Z Evid Fortbild Qual Gesundhwes. 2013;107(9-10):646-64 [PMID: 24315336]
  42. BMJ. 2011 Oct 18;343:d5928 [PMID: 22008217]
  43. Chest. 2013 Nov;144(5):1615-1621 [PMID: 23828253]
  44. CA Cancer J Clin. 2023 Jan;73(1):17-48 [PMID: 36633525]
  45. JAMA. 2006 Feb 8;295(6):676-80 [PMID: 16467236]
  46. BMJ. 2001 Jul 14;323(7304):101-5 [PMID: 11451790]
  47. Eur J Cardiothorac Surg. 2002 Mar;21(3):520-6 [PMID: 11888774]
  48. Stat Med. 1998 Dec 30;17(24):2815-34 [PMID: 9921604]
  49. Ann Surg. 2002 Jan;235(1):133-9 [PMID: 11753052]
  50. Ann Thorac Surg. 1996 Jan;61(1):177-82; discussion 183 [PMID: 8561549]
  51. BMJ. 2003 Sep 6;327(7414):557-60 [PMID: 12958120]

MeSH Term

Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Systematic Reviews as Topic
Meta-Analysis as Topic
Lymph Node Excision
Research Design

Word Cloud

Created with Highcharts 10.0.0willmediastinaloutcomeslymphadenectomyNSCLCresearchsurvivalpatientsstageI-IIIAsearchLungcancernon-smallcelllungpotentialongoingassesscompleteCMLselectiveSMLANDprotocolrecommendedPreferredReportingItemsSystematicReviewMeta-Analysismeta-analysisconductedaccordanceCochranecomprehensiveTwoSciencepublicationOSDFSsecondary1-year3-year5-yearratesqualityanalysesanalysisreviewINTRODUCTION:remainslargestcausecancer-relateddeathsworldwideSurgicalremovalachievecurealthoughdebateregardingsignificanceremovingnodesoptimalextentlymphnodeexcisionpurposediagnosedreceivedeitherMETHODSANALYSIS:followsguidelinesProtocolsstandardmethodologyCollaborationreportedReviewsMeta-Analyses2020guidanceconductrandomisedcontrolledtrialsnon-randomisedstudiesexaminingeffectivenesscomparedauthorsperformMEDLINE/PubMedEmbaseLibraryCNKIWanFangSinomedVIPWebdatabasesrestrictionslanguagedate10April2024searchesnewReferencelistsalsocheckedpertinentjournalshandsearchedprimaryincludeoveralldisease-freeconsistindependentreviewersscreenextractdataevaluatebiasselectedthirdactingarbitratorSubgroupsensitivityplannedevidenceevaluatedusingGradingRecommendationsAssessmentDevelopmentEvaluationManagerV54usedsynthesisprocessETHICSDISSEMINATION:Ethicalapprovalnecessarystudybasedliteratureresultssubmittedreportingpeer-reviewedSTUDYREGISTRATION:OpenFrameworkhttps://doiorg/1017605/OSFIO/PN7UQSurvivalfollowingcancer:systematicDiseasesONCOLOGYSURGERY

Similar Articles

Cited By